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INTRODUCTION 
 
HISTORY OF LARYNGOSCOPY AND INTUBATION 
      In 1854, a  Spanish vocal Pedagogist, Manuel Garcia (1805-1906) 
became the first man to visualize the functioning glottis in a human 
being. 
     On 23rd April 1895,  Alfred  Kirsten performed the first direct 
laryngoscopy. 
    In 1880 Scottish surgeon, William Macewen, (1848-1924) reported use 
of orotracheal intubation as an alternative to tracheotomy. 
     In 1913 Chevalier Jackson, reported high success in direct 
laryngoscopy. 
      Sir Robert Reynolds Macintosh (1897-1989), introduced his new 
curved laryngoscopy blade in 1943. 
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RESPONSE TO LARYNGOSCOPY 
      The induction of anaesthesia, laryngoscopy , tracheal intubation and 
surgical stimulation evoke cardiovascular responses leading to alteration 
in heart rate, cardiac rhythm and blood pressure. The response starts in 5 
seconds , peaks within 1-2 minutes and returns to baseline in 5 minutes. 
     This sympatho adrenal response is of little significance in healthy 
patients but hazardous in patients with hypertension, coronary artery 
disease, cerebrovascular disease, intracranial pathology and hyperactive 
airways. In these patients the stress response should be attenuated. 
     Prof. King et al., in 1951 documented myocardial ischemic changes 
following laryngoscopy and intubation with increase in systolic blood 
pressure upto 40mmHg even in normotensive patients. 
      Various drugs are used to attenuate this stress response like local 
anaesthetics, narcotics, vasodilators, beta blockers, calcium channel 
blockers, Magnesium and centrally acting sympatholytics. 
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       In the Institute of Anaesthesiology and critical care, Madras Medical 
College and Rajiv Gandhi Government General Hospital we have 
compared Esmolol and Magnesium Sulphate with placebo in attenuating 
hemodynamic stress response to laryngoscopy and intubation. 
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AIM OF THE STUDY 
 
          The haemodynamic stress response to laryngoscopy and intubation 
should be attenuated to balance myocardial oxygen supply and demand 
especially in coronary artery disease patients. It is also hazardous in 
patients with cerebrovascular disease, intracranial pathology and 
hyperactive airways. The aim of this study is to compare the effectiveness 
of Esmolol and Magnesium Sulphate for attenuation of haemodynamic 
stress response to laryngoscopy and intubation. 
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ANATOMY OF LARYNX 
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NERVE SUPPLY OF LARYNX 
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ANATOMY AND NERVE SUPPLY OF LARYNX 
     The pharynx is divided into nasopharynx, oropharynx and 
laryngopharynx. The epiglottis seperates the oropharynx from the 
laryngopharynx. 
      The palatine branch of the trigeminal nerve supplies the hard and soft 
palate. The anterior two third of the tongue is supplied by the lingual 
nerve and glossopharyngeal nerve supplies the posterior one third of the 
tongue. The glossopharyngeal nerve also supplies the roof of the pharynx. 
      The pharyngeal surface of the epiglottis is supplied by the 
glossopharyngeal nerve and the laryngeal surface is supplied by the 
vagus. The sensory supply of the supraglottic area is by the internal 
branch of superior laryngeal nerve.The motor branch of the recurrent 
laryngeal nerve supplies all the intrinsic muscles of the larynx except the 
cricothyroid, which is supplied by the external laryngeal nerve and the 
sensory branches of the recurrent laryngeal nerve supply the mucosa of 
the larynx below the vocal cords. 
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PHYSIOLOGY OF STRESS RESPONSE 
     The larynx is a heavily innervated sensory structure, so laryngoscopy 
and tracheal intubation stimulates these structures leading to the stress 
response. Hemodynamic stress response to laryngoscopy and intubation 
occurs as increase in heart rate and blood pressure due to reflex 
sympathetic discharge. The  force and duration of laryngoscopy, hypoxia, 
hypercarbia, stimulation of carina by endotracheal tube , repeated and 
prolonged attempts affect the stress response. 
      This stress response starts within 5 seconds peaks within 1-2 minutes 
and returns to baseline in five minutes. This sympatho adrenal response is 
of little significance in healthy patients but hazardous in patients with 
hypertension, coronary artery disease , intra cranial pathology and 
hyperactive airways. 
CARDIOVASCULAR RESPONSE: 
Hypertension, tachycardia, bradycardia and dysrhythmias mediated 
by autonomic nervous system occurs. Hypertension, tachycardia , 
increase in cardiac work and oxygen consumption are mediated by 
sympathetic afferents via the cardioaccelerator fibres and sympathetic 
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chain ganglia. The polysynaptic pathway from 9th and 10th nerve 
afferents to sympathetic nervous system in the brain stem and spinal cord 
results in a diffuse autonomic response which includes widespread 
release of norepinephrine from the adrenergic terminals and release of 
epinephrine from the adrenal medulla. 
 
One other reason for the hypertensive response is due to activation 
of renin- angiotensin system with release of renin from the renal 
juxtaglomerular apparatus, an end organ innervated by adrenergic nerve 
terminals. 
Bradycardia caused by a rise in vagal tone in Sino atrial node is a 
monosynaptic reflex to a noxious stimuli. 
 
RESPIRATORY SYSTEM: 
1) Reflex glottis closure-laryngospasm 
2) Decreases dead space 
3) Increased airway resistance 
4) Bronchospasm 
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STRESS RESPONSE IN PATHOLOGICAL STATES: 
     1) In patients with limited myocardial reserve , myocardial ischemia 
and failure can occur. It is essential to maintain the heart  rate and blood 
pressure of the patient within 20% of the normal awake value. Heart rate 
should ideally be less than 110 beats per minute(ischemic threshold). 
     2) Intracranial vascular anomalies can rupture. 
     3) In patients with hyperactive airways bronchospasm and 
laryngospasm can occur. 
     4) Laryngoscopy and intubation can increase cerebral blood flow if 
autoregulation is impaired. The resultant increase in intracranial pressure 
can lead to brainstem herniation and death. 
  11
 
METHODS TO ATTENUATE  INTUBATION RESPONSE: 
     1) Maintaining a deep plane of general anaesthesia using volatile 
anaesthetics. This dose of volatile anaesthetics required to block the 
cardiovascular responses to endotracheal intubation  may result in 
profound cardiovascular depression. The volatile agents used are 
Halothane, Isoflurane and Sevoflurane. 
    2) Local anaesthetics . Lignocaine is used. 
          a) It is given as viscous gargle for oropharyngeal anaesthesia. 
          b) aerosol for intratracheal anaesthesia  
           c) intravenous 
          d) local instillation or topical spray over the vocal cords. 
          e)Regional nerve blocks 
    3) Vasodilators –Nitroglycerine 
                                Sodium Nitroprusside 
                                Hydralazine 
    4) Magnesium sulphate 
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    5) Narcotics –Fentanyl, Sufentanil, Remifentanil, Morphine, Pethidine. 
Fentanyl is the most commonly used narcotic.It is a potent analgesic, has 
a short duration of action, does not increase intracranial tension and has 
minimal circulatory changes. 
     6) Calcium channel blockers- Nifedipine, Nicardipine, Verapamil, 
Diltiazem 
    7) Adrenergic  blockers –Beta blocker-Metoprolol, Esmolol 
                                           -Alpha blocker-Phentolamine 
                                           Alpha and beta blocker-Labetalol 
    8) Central sympatholytics-Clonidine and Dexmedetomidine. They act 
by   decreasing central sympathetic outflow. 
    9)Sedatives and anxiolytics. 
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PHARMACOLOGY OF ESMOLOL 
INTRODUCTION: 
     Esmolol is a beta adrenergic receptor antagonist. It binds to beta 
receptors and interferes with the ability of catecholamines to provoke a 
response. 
 
STRUCTURE: 
     It is methyl p-(2-OH-3-isopropylaminopropoxy)hydrocinnamate 
hydrochloride. 
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     The ester group in the para position accounts for high metabolic 
lability and short duration of action.  This para substitution also confers 
cardioselectivity on Esmolol. 
Mol.formula-C16H26NO4Cl 
Molecular weight -331.8 
MECHANISM OF ACTION: 
    Esmolol competitively inhibits beta adrenergic receptors. Beta 
receptors are G-protein coupled receptors and when stimulated activate 
adenylcyclase to produce cAMP.Net effect of beta stimulation is positive 
chronotropic, inotropic and dromotropic effect. Esmolol produces 
negative  chronotropic, inotropic and dromotropic effect. 
CLASSIFICATION: 
It is a cardio selective beta 1 blocker. 
PROPERTIES: 
   1) No significant intrinsic sympathomimetic activity 
   2) Membrane stabilizing effect at therapeutic doses 
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   3) Cardioselective 
   4) 55% is protein bound 
   5) Clearance is by ester hydrolysis of the methyl side chain,  so it has 
short duration of action 
   6) It has no active metabolites 
   7) Elimination half time is 9 minutes. 
   8) Distribution half-life is 2 minutes 
   9) It has rapid onset and short duration of action. Therapeutic effect 
occurs within 5 minutes that ceases within 10-30 minutes. 
 
PHARMACOKINETICS: 
     Elimination half life is 9 minutes due to rapid hydrolysis by esterases 
in the cytosol of red blood cells. Elimination is independent of hepatic 
and renal function and plasma choline esterases. Distribution half life is 2 
minutes. The major fraction of Esmolol is detectable in urine as acid 
metabolites which have longer elimination half life (4 hours) and slower 
clearance. However , the metabolites have only weak beta blocking 
actions which is about  1500 times less than the parent compound. 
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DOSE AND PREPARATION: 
     Loading dose is 0.5mg/kg over 60 seconds followed by infusion rate 
of 50-300 microgm/kg/min. Each ml contains 10mg Esmolol 
Hydrochloride , buffered with sodium acetate trihydrate and glacial acetic 
acid. Hydrochloric acid is added to adjust pH  around 4.5-5.5 
EFFECTS ON VARIOUS SYSTEMS: 
1) CARDIO VASCULAR SYSTEM: 
     It decreases the heart rate, rate pressure product, cardiac index, 
systolic blood pressure and ejection fraction. It also decreases the rate of 
spontaneous phase 4 depolarisation.  It has negative chronotropic,  
inotropic and dromotropic effects. It produces peripheral vasoconstriction 
due to unopposed alpha effect. 
2) RESPIRATORY SYSTEM: 
     There is no bronchoconstriction since it is a cardioselective beta 
blocker. 
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3) METABOLIC EFECT: 
     It can lead to unrecognized hypoglycemia since tachycardia as a 
warning sign is blunted. It inhibits uptake of potassium into cells leading 
to hyperkalemia. 
4) NERVOUS SYSTEM: 
Fatigue and lethargy since it crosses the blood brain barrier. 
5) FETUS: 
Bradycardia, hypotension, hypoglycemia 
6) WITHDRAWAL HYPERSENSITIVITY: 
     Acute withdrawal can lead to excess sympathetic nervous system 
activity in 24-48 hours due to up regulation of beta receptors. 
CONTRA INDICATIONS: 
   1) Heart block – second and third degree 
   2) Cardiogenic shock-rarely associated with cardiovascular collapse in 
patients with compensatory tachycardia secondary to hypovolemia, 
cardiac failure or acute myocardial infarction. 
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ADVERSE EFFECTS: 
Bradycardia, hypotension, deterioration (worsening) of heart failure, 
rebound ischemia, bronchoconstriction and fatigue. 
DRUG INTERACTIONS: 
   1) There is 10-20% increase in digoxin levels. 
   2) Bradycardia and myocardial depression can occur with anaesthetic 
agents. 
   3) Morphine and Warfarin increase the steady state levels of Esmolol. 
   4) The duration of block by succinyl choline may be prolonged. 
  5) Esmolol should not be concomitantly administered  with calcium 
channel blockers in patients with conduction abnormalities and left 
ventricular dysfunction. 
CLINICAL USES: 
   1) Perioperative beta blockade 
   2) To attenuate intubation response. 
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   3) Class –II anti arrhythmic effect. It is used in treatment of 
supraventricular  
tachycardia , to convert atrial fibrillation to sinus rhythm. 
   4) To treat hypertension and tachycardia during surgery. 
   5) Myocardial ischemia 
   6) Thyrotoxicosis 
   7) Miscellaneous-glaucoma, prophylaxis of migraine, essential tremor 
  20
PHARMACOLOGY OF MAGNESIUM SULPHATE 
 
INTRODUCTION: 
Magnesium is the fourth important cation in the body. It is the second 
most important intracellular cation after potassium. 
ROLE OF MAGNESIUM: 
i. Cardiac cell membrane ion transport  
ii. Enzyme activity (ATP) 
iii. Physiological Antagonist of calcium 
iv. Analgesia (Antagonism of NMDA receptors) 
v. Systemic vasodilation 
vi. Coronary vasodilation 
vii. Inhibits platelet function 
viii. Decreases reperfusion injury 
MECHANISM OF ACTION: 
    It is a physiological and pharmacological blocker of N-methyl- D- 
aspartate receptors in neuronal tissue. It also inhibits calcium mediated 
neuroendocrine secretion and release of catecholamines. 
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     It potentiates neuromuscular blockade by competing for calcium 
channels in pre-synaptic nerve terminal and inhibits acetyl choline release 
at the motor end plate. 
Properties: 
i. Antagonism of NMDA receptors is used for acute and 
chronic pain control. 
ii. Used in hypotensive anaesthesia in middle ear surgeries. 
iii. Inhibits catecholamine release in pneumo peritoneum in 
laparoscopic cholecystectomy. 
iv. Decreased incidence of nausea and vomiting. 
v. Decreased requirement for rescue antiemetics. 
vi. Decreased incidence of post operative shivering. 
vii. Decreased anaesthetic requirement. 
viii. Myocardial protection. 
ix. Improved control of asthma. 
x. Used in tocolysis. 
xi. Management of intra operative hypertensive events. 
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HYPOMAGNESEMIA: 
Serum concentration is less than 1.6meq/litre. 
Causes: 
i. Chronic alcoholism 
ii. Hyperalimentation 
iii. Malabsorption 
iv. Diuretic therapy  
v. Drugs-cyclosporine 
vi. Hypokalemia 
Symptoms of hypomagnesemia: 
- Neuromuscular manifestations resembling hypocalcemia 
like stridor, chvosteks sign, carpopedal spasm, trousseau’s 
sign 
- Skeletal muscle weakness 
- Ventricular dysrhythmias 
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Treatment: 
Magnesium Sulphate 1-2 g IV over 5-60 minutes 
 
HYPERMAGNESEMIA: 
Serum concentration of Magnesium >2.6mEq/litre. 
Cause: 
1) Parenteral Magnesium to treat PIH 
2) Chronic renal failure 
Symptoms: 
1. Sedation 
2. Myocardial depression 
3. Suppression of neuromuscular transmission 
4. Direct relaxant effect on skeletal and smooth muscle 
5. Potentiation of non depolarizing muscle relaxants 
6. Diminished deep tendon reflexes when serum Magnesium 
>10mEq/litre 
7. Skeletal muscle paralysis, apnea and heart block when 
serum Magnesium >12mEq/litre 
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Treatment: 
   1) IV Fluids 
   2) Drug induced diuresis 
   3) 10%Calcium gluconate 10-15mg/kg IV 
 
CLINICAL USES OF MAGNESIUM: 
1) Pregnancy induced hypertension 
Initial dose is 40-60mg/kgIV followed by an infusion 15-30mg/kg/hr 
to maintain therapeutic serum concentration of 4-6mEq/litre. In 
eclampsia it produces cerebral vasodilation, protects the blood brain  
barrier and has anticonvulsant properties. 
Normal serum concentration---1.8-2.5mEq/l 
Therapeutic level---4-7mEq/l 
Loss of patellar reflex---7-10mEq/l 
Respiratory depression---10-13mEq/l 
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Heart block---15-25mEq/l 
Cardiac arrest--- >25mEq/l 
2) Treatment of cardiac dysrhythmias and hypertension: 
Initial dose of 2g IV administered over 5 minutes  followed by 
infusion      
1-2g/hour. 
3) Cardioprotective effects 
Used in patients who develop torsades de pointes type of ventricular 
tachycardia following acute myocardial infarction .In the 
cardiovascular system it produces arteriolar vasodilation, minimal 
venodilation, maintains cardiac filling and cardiac output. 
4) Trial use in catecholamine excess states  like 
pheochromocytoma and tetanus where magnesium limits 
catecholamine release are being tried. 
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CONTRAINDICATIONS: 
  1) Renal failure-since magnesium is excreted by the kidneys 
  2) Digitalis use 
  3) In patients on CNS depressants 
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REVIEW OF LITERATURE 
 
KING et al., in 1951, showed that there was a marked rise in blood 
pressure and heart rate during laryngoscopy which was due to the 
mechanical stimulation of sensitive receptors in the area of epiglottis. 
 
SANTHOSH KUMAR ,SAPNA BATHLA  et al 4.,in 2003, compared 
the efficacy of intravenous Esmolol, Magnesium Sulphate and Diltiazem 
in attenuating hemodynamic stress response to laryngoscopy and 
intubation. 
 
Method: 
  One hundred and ninety normotensive patients of ASA PS I and II, 15-
55 years were randomized into four groups placebo, Esmolol, Magnesium 
Sulphate and Diltiazem.They were premedicated with Injection 
Glycopyrrolate and Diazepam forty five minutes before surgery. 
Anaesthesia was induced with Thiopentone and vecuronium. Esmolol 
2mg/kg or Diltiazem 0.2mg/kg and Magnesium Sulphate 60mg/kg were 
given one minute after vecuronium and intubation was done two minutes 
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after the drugs. Blood pressure and heart  rate were measured  baseline, 
after drug, immediately after intubation, one minute, three minutes and 
five minutes after intubation 
 
Conclusion: 
   Magnesium Sulphate produced tachycardia and fails to attenuate rise in 
heart rate. Esmolol prevented rise in heart rate, though rise in blood 
pressure was suppressed and not prevented by this dose of Esmolol. 
 
MICHAEL F M JAMESet.al 5.,in 1989, showed that IV Magnesium 
Sulphate inhibits catecholamine release associated with tracheal 
intubation. 
Method: 
Thirty patients of ASA PS I and II, 15-51 years old were divided into two 
groups placebo and Magnesium Sulphate .They were premedicated with 
Diazepam 10mg. Anaesthesia was induced with Thiopentone and MgSo4 
60mg/kg or normal saline was given. Succinylcholine was given and 
patient was intubated. Blood pressure, heart rate , serum magnesium and 
catecholamine levels were measured upto five minutes after intubation. 
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Result: 
Magnesium Sulphate 60mg/kg pretreatment increased the heart rate by 
13±3.9 beats/min. After intubation heart rate was unchanged in MgSO4 
group but increased in control group. Norepinephrine and epinephrine 
levels increased significantly in control group compared to MgSO4 
group. Blood pressure was also significantly elevated in the control 
group. 
Conclusion: 
   Magnesium Sulphate significantly attenuated catecholamine mediated 
stress response. 
 
A.A.VANDENBERG et al 1.,in 1997, compared Magnesium Sulphate, 
Esmolol , Lignocaine, Nitroglycerine and placebo for attenuation of 
hemodynamic responses to noxious stimuli in patients undergoing 
cataract surgery.  
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Method: 
    100  middle age to elderly patients with diabetes, hypertension or 
ischemic heart disease  coming for cataract surgery  were given 
Magnesium sulphate 40 mg/kg, Lignocaine 1.5mg/kg, Nitroglycerine 7.5 
microgm/kg  and Esmolol 4 mg /kg at induction of anaesthesia. Heart 
rate, blood pressure, rate pressure product and pressure rate quotient were 
measured until five minutes after intubation. 
Result: 
     Esmolol prevented increase in heart rate and rate pressure product. 
Magnesium did not prevent response to laryngoscopy and intubation and 
there was increase in rate pressure product. 
 
JUHI SHARMA et al 2 in 2006,  compared efficacy of Esmolol and 
Magnesium Sulphate in attenuating pressor response to intubation in 
controlled hypertensive patients. 
 
Method: 
   Sixty ASA II patients 45-65 years with controlled hypertension for 
elective surgery were allotted into three groups. They received MgSo4 
  31
40mg/kg, Esmolol 1.5mg/kg or Placebo. Anaesthesia was induced with 
Thiopentone and succinylcholine 1.5mg/kg. Heart rate and blood pressure 
was measured upto five minutes after intubation. 
Result: 
    There was no significant difference in systolic and diastolic blood 
pressure between MgSo4 and Esmolol group. There was significant rise 
in heart rate in MgSo4 group. 
 
D.LEE et al 30in 2009, showed that magnesium Sulphate attenuates 
blood pressure response during laparoscopic cholecystectomy. 
Method: 
   Thirty two patients undergoing laparoscopic cholecystectomy were 
divided into two groups placebo and MgSo4 50mg/kg. Arterial pressure, 
heart rate, serum magnesium, plasma renin activity, cortisol, vasopressin 
and catecholamine levels were measured. 
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Result: 
   Blood pressure, norepinephrine and epinephrine levels increased in 
placebo group.There was no significant difference in renin and cortisol 
levels. 
Conclusion: 
   Magnesium Sulphate attenuates blood pressure response due to 
decreased release of vasopressin and catecholamine levels.  
 
R. W.ALLEN et al 6., in 1990, studied attenuation of pressor response to 
tracheal intubation in 69 patients  with moderate to severe gestational 
proteinuric hypertension with ligocaine, Alfentanil  and magnesium 
sulphate. No mean increase in  systolic blood pressure occurred in 
MgSO4 group. 
 
D.H. LEE et al 8 in 2009,  showed that MgSO4 as an adjuvant  during 
general anaesthesia for caesarean section avoided perioperative 
awareness and pressor response from inadequate analgesia. 
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K.PASTERNAK et al  9  in 2006, showed the effect of preoperative 
Magnesium  supplementation in CABG patients. Magnesium attenuates 
adrenergic response to intubation. 
 
B.UGUR et al 10 in 2007, showed that Esmolol 1.5 mg/kg prevents 
tachycardia and increase in rate pressure product caused by laryngoscopy 
and intubation in patients with tachycardia. 
 
J.H.RYU et al 11 in2009,  showed that MgSO4 provided adequate 
hypotensive anaesthesia  and favourable post operative course with better 
analgesia , less shivering and less postoperative nausea and vomiting in 
middle ear surgeries. 
 
E.FIGUEREDO et al 12 in 2001,  did a meta analysis on the assessment 
of efficacy of various doses and regimes of  Esmolol on haemodynamic 
changes induced by laryngoscopy and tracheal intubation. Various trials 
were performed and they measured heart rate, systolic blood pressure, 
diastolic blood pressure and mean arterial blood pressure preinduction, 
immediately prior to intubation and post intubation. They showed that 
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Esmolol is effective for attenuation of adrenergic response and preferred 
to use it as a continuous infusion. The most effective dose was loading 
dose of Esmolol 500microgm/kg/min followed by an infusion of   200-
300microgm/kg/minute. 
 
K.MONTAZERI et al 13 in 2005, showed that pre treatment with 
different doses of MgSO4 decreased cardiovascular responses to 
laryngoscopy and intubation than lignocaine. 
 
A.GUPTA et al 3 in 2009,  compared Esmolol and MgSo4 for 
attenuation of stress response to laryngoscopy and intubation. 
Method: 
     Sixty ASA I and II patients 20-40 years, were divided into three 
groups placebo, Esmolol 1.5mg/kg and Lignocaine 1.5mg/kg. 
Anaesthesia was induced with Thiopentone and Succinylcholine. Blood 
pressure and heart rate  was measured upto five minutes after intubation. 
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Result: 
Esmolol showed greater attenuation of heart rate and blood pressure  than 
lignocaine. 
 
MICHAEL.F.JAMES et al 32in 2005, compared Remifentanil and 
MgSo4 for attenuation of hemodynamic response to electro convulsive 
therapy. 
Method: 
Twenty patients underwent anaesthesia 115 times and were allotted into 
three groups placebo, Magnesium Sulphate and Remifentanil. 
Anaesthesia was induced with Thiopentone 4mg/kg and Succinylcholine 
0.5mg/kg. Remifentanil  1microgm/kg amd MsSo4  30mg/kg were given. 
Heart rate and blood pressure was measured 0,1, 3, 5,10 minutes after 
seizures. 
Conclusion: 
      They concluded that Remifentanil and Magnesium Sulphate 
attenuated systolic blood pressure response to ECT. Remifentanil but not 
Magnesium Sulphate suppressed heart rate response to electro convulsive 
therapy. 
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RENITA MARINA PINTO et al 31in 2007,compared hemodynamic 
stress response to laryngoscopy and intubation in hypertensive patients. 
Esmolol 2mg/kg and Magnesium Sulphate 50mg/kg was used. They 
concluded that both attenuated pressor response in well controlled 
hypertensive patients and that both are safe and effective. 
 
DILIP KOTHARI et al 15in 2008, compared efficacy of intravenous 
MgSo4 and fentanyl on circulatory changes during anaesthesia. They 
concluded that there was significant increase in heart rate after injection 
.They said that magnesium is a cheap alternative to fentanyl. 
 
A.AHMED et al 17 in 2009,showed that MgSo4 50mg/kg attenuates 
stress response to laryngoscopy and intubation. 
 
SHARMA et al 23 in 1996,  compared various doses of Esmolol like 100 
and 200 mg in  attenuating  stress response to laryngoscopy and 
intubation in hypertensive patients. They concluded that Esmolol 200mg 
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produced diastolic blood pressure less than baseline values and Esmolol 
100mg is safe. 
 
FUGHS et al 29 in 1995, studied the interaction of Magnesium Sulphate 
with  vecuronium induced neuromuscular block. They allocated patients 
into two groups.  One group received Magnesium Sulphate 40mg/kg in 
100 ml saline as an infusion over ten minutes before induction and the 
other group received 100ml of saline as a placebo. 
Observation:  
Plasma magnesium concentrations  increased from a baseline 
concentration 
of 0.9(0.06) to 1.08 (0.07) mmol/ litre 15 min after the MgSO4 infusion 
(P < 0.05); in controls plasma magnesium concentrations were 0.86 
(0.08) mmol/ litre  before and 0.87 (0.6) mmol/l after saline infusion. A 
hot flush of the lower abdomen was reported by 21 of the 55 patients. 
 
Conclusion: 
 
They concluded that MgSO4, administered before vecuronium, 
accelerated the onset of neuromuscular block necessary for intubation of 
the trachea, that MgSO4 in the presence of vecuronium intensified and 
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prolonged neuromuscular block, and that monitoring of neuromuscular 
function and reduction in dose of vecuronium are required when using 
these two drugs in combination. 
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MATERIALS AND METHODS 
    
     Ninety patients of ASA physical status I and II undergoing elective 
ENT surgeries under general anaesthesia with endotracheal intubation 
were included in the study. 
     Patients in the age group 15-60 years of both sexes were included. It is 
a prospective randomized single blinded study. The study was approved 
by our institute ethical committee and after obtaining informed written 
consent from the patient, this study was conducted. 
    This study was done during the period from September 2012 to 
November 2012, in the Institute of Anaesthesiology and critical 
care,Rajiv Gandhi Government General Hospital, Chennai -600003. 
  
INCLUSION CRITERIA: 
• Age         :15 – 60 years 
• ASA         : I & II 
• Surgery  : Elective ENT  surgery 
• Who have given valid informed consent.  
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EXCLUSION CRITERIA: 
• Not satisfying inclusion criteria.  
• Patients with anticipated difficult intubation 
• Uncontrolled hypertension and diabetes 
• History of cardiac illness 
• Neuromuscular disorders 
• Hepatic disease 
• Renal disease 
• known sensitivity to the drugs  
• cerebrovascular disease 
• Emergency surgery 
• Bronchial asthma  
• Patients on alpha and beta blockers 
Materials:  
• Laryngoscope blades of various sizes, bougie, oropharyngeal 
airway 
• Drugs – Propofol, Sevoflurane, Fentanyl, Glycopyrrolate, 
Midazolam,Normal saline,Vecuronium, Ephedrine, 
Atropine, Esmolol Magnesium Sulphate, Neostigmine,  
Calcium gluconate and other emergency drugs. 
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• Monitors – ECG, NIBP, SPO2, EtCO2 
• 2 cc, 5 cc and 10 cc syringes 
• 18G intravenous cannula. 
• Appropriate size endotracheal tubes 
 
METHODS:  
Pre anaesthetic preparation: 
      All the patients were admitted in the wards as inpatients and routine 
investigations were done. 
i. Complete blood count 
ii. Blood urea and sugar 
iii. Serum creatinine and electrolytes 
iv. chest x-ray 
v. Electrocardiogram  
vi. Other investigations like liver function test and coagulation profile 
were asked for if needed. 
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Anaesthetic Protocol: 
      Pre operative visit was done to allay the anxiety of the patients and 
good rapport was established with the patients. 
      All patients were given pre operative night sedation with tablet 
Alprazolam 0.25mg. 
     Tablet Ranitidine 150mg and tablet Metoclopramide 10mg was given 
with sips of water at 6 AM. 
Monitors: 
   Induction of anaesthesia was standardized for all patients. Monitors 
used were NIBP, ECG, EtCo2 and pulse oximetry. 
METHOD: 
      90 patients of age group 15 to 60 yrs of ASA physical status I and II  
who underwent elective ENT surgery under general anesthesia were 
selected and randomly allocated into 3 groups. Baseline heart rate and 
blood pressure was measured. They were premedicated with 
Inj.Glycopyrrolate 0.2mg and Inj.Midazolam 0.04mg/kg intramuscular  
45 minutes before surgery. Patients were then shifted into the theatre. Inj. 
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Fentanyl 2µg/kg was given 5 minutes before intubation to all patients. 
They were induced with Inj. Propofol 2mg/kg and Vecuronium 0.1mg/kg. 
Nitrous oxide and Oxygen in a ratio of 66:33 and Sevoflurane 2% was 
given to the patient. 
 
     Group E received Esmolol 1.5mg/kg in 15ml normal saline over 15-20 
seconds  one minute after vecuronium  and intubation was done after 2 
minutes. 
   
    Group M received Inj.Magnesium Sulphate 50mg/kg in 100ml of 
normal saline infusion over 10 minutes before induction. 
 
   Group P received 15ml of normal saline 5 minutes before induction.   
 
    The heart rate, systolic and diastolic blood pressure and mean arterial 
pressure were recorded baseline, after premedication, one min after test 
drug, after induction, immediately after  intubation, thereafter 1, 3 and 5 
minutes following intubation. Laryngoscopy duration and Cormack 
Lehane score were noted. Any incidence of hypotension, bradycardia or 
arrhythmias was noted. 
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      No surgical stimulation or change in position was permitted for five 
minutes after intubation. Anaesthesia was maintained with N2O:O2 in a 
ratio of 66:33 , vecuronium 0.01mg/kg and sevoflurane 1-2% as needed. 
 
      All patients were reversed with Inj. Glycopyrrolate 0.01mg/kg and 
Neostigmine 50microgm/kg and extubated after reversal of 
neuromuscular blockade.  
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PRIMARY OUTCOME MEASURES:  
• Heart rate, systolic blood pressure , diastolic blood pressure, 
mean arterial pressure  
 
DATA   ANALYSIS: 
       ANOVA and Pearson chi square test were used. A  p value of <0.05  
was considered as statistically significant. Tukey’s HSD was used to 
compare between the groups.   
 
 
 
                                                                       
 
 
 
 
 
  46
 
OBSERVATIONS AND RESULTS 
 
     Ninety patients under this study were allotted into three groups, 
Group P- Placebo 
Group E- Esmolol  
Group M  Magnesium sulphate  
With thirty patients  in each group. They comprised of both sexes in the 
age group 15-60 years. The demographic profile is as follows, 
 
Characteristics Group P Group E Group M 
Age (yrs) 29.7±10.06 26.53±9.32 31.13±9.20 
Sex 
Male 11 13 11 
Female 19 17 19 
Weight (kg) 56.27±8.09 52.93±10.65 52.67±8.92 
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Age group (Years) 
Group N Mean SD ANOVA 
P 30 29.70 10.06 F = 1.829 
p = 0.167 
  
E 30 26.53 9.32 
M 30 31.13 9.20 
     In group P, the mean age was 29.7±10.06, ranging from 16-52 yrs. In 
group E, the mean age was 26.53±9.32, ranging from 15-60 yrs. In group 
M, the mean age was 31.13±9.20, ranging from 16-45 yrs. 
     The p value is 0.167. Hence there is no statistical significance in age 
between the three groups (p value of significance is < 0.05) 
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Sex Distribution 
Sex Group P Group E Group M Total 
p = 0.829 
Male 11 13 11 35 
Female 19 17 19 55 
Total 30 30 30 90 
      
     By Pearson Chi square test p = 0.829. Hence there is no statistical 
significance in sex between the three groups. 
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Weight Distribution (kg) 
Group N Mean SD ANOVA 
P 30 56.27 8.09 
F = 1.401 
p = 0.252 
E 30 52.93 10.65 
M 30 52.67 8.92 
 
In group P, the mean weight was 56.27±8.09, ranging from 38-71kg. In 
group E, the mean weight was 52.93±10.65, ranging from 35-70kg. In 
group M, the mean weight was 52.67±8.92, ranging from 35-74kg. 
p value = 0.252. Hence there is no statistical significance in weight 
distribution between the three groups. 
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Baseline Hemodynamic Parameters 
Basal Heart rate (beats/min) 
Group N Mean SD ANOVA 
P 30 79.80 14.44 
F = 3.690 
p = 0.112 
E 30 86.67 9.79 
M 30 81.47 14.47 
 
p value = 0.112. Hence there is no statistical significance in basal heart 
rate between the three groups. 
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Basal systolic pressure (mmHg) 
Group N Mean SD ANOVA 
P 30 125.73 10.72 
F = 0.690 
p = 0.504 
E  30 123.13 8.69 
M 30 125.90 11.12 
 
p value = 0.504. Hence there is no statistical significance in basal systolic 
pressure between the three groups. 
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Basal diastolic pressure (mmHg) 
Group N Mean SD ANOVA 
P 30 81.33 6.70 
F = 0.348 
p = 0.707 
E 30 80.00 6.50 
M 30 81.33 8.12 
 
p value = 0.707. Hence there is no statistical significance in basal 
diastolic pressure between the three groups. 
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Basal mean arterial pressure (mmHg) 
Group N Mean SD ANOVA 
P 30 95.93 7.46 
F = 0.613 
p = 0.544 
E 30 94.07 6.60 
M 30 96.00 8.81 
 
p value = 0.544. Hence there is no statistical significance in basal mean 
arterial pressure between the three groups. 
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HEART RATE CHANGES (beats / min) 
Group P E M p Value 
Baseline 79.80±14.44 86.67±9.79 81.47±14.47 0.112 
After 
Premedication 79.83±13.05 86.63±14.30 84.53±16.50 0.191 
After Test 
Drug 77.30±11.30 77.70±13.14 93.27±18.45 0.001 
After 
Induction 72.27±13.26 82.20±15.00 78.33±11.31 0.017 
Immediately 
After 
Intubation 103.63±12.31 90.67±13.93 97.40±12.57 0.001 
1 minute  
After 
Intubation 95.87±12.86 87.27±13.48 92.97±10.38 0.026 
3 minutes  
After 
Intubation 87.83±12.50 84.30±12.79 90.07±9.82 0.167 
5 minutes  
After 
Intubation 81.73±13.66 81.60±13.31 86.00±9.61 0.296 
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SYSTOLIC BLOOD PRESSURE CHANGES (mmHg) 
 
Group P E M p Value 
Baseline 125.73±10.72 123.13±8.69 125.90±11.12 0.504 
After Premed 123.47±10.54 120.67±9.05 120.30±9.56 0.391 
After Test Drug 118.70±13.64 100.10±9.60 112.27±11.65 0.001 
After Induction 109.97±13.63 107.70±9.23 98.97±9.74 0.001 
Immediately 
After 
Intubation 138.57±17.25 114.43±8.76 124.90±17.76 0.001 
1 minute  After 
Intubation 128.73±17.04 107.60±9.23 116.80±15.66 0.001 
3 minutes  
After 
Intubation 119.13±16.16 102.60±9.61 109.80±14.75 0.001 
5 minutes  
After 
Intubation 111.23±14.34 100.20±9.44 105.47±10.84 0.002 
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DIASTOLIC BLOOD PRESSURE CHANGES (mmHg) 
 
 
Group P E M p Value 
Baseline 81.33±6.70 80.00±6.50 81.33±8.12 0.707 
After Premed 78.40±6.89 76.33±5.82 77.30±8.61 0.541 
After Test Drug 76.93±7.38 61.90±8.22 69.70±9.63 0.001 
After Induction 71.27±10.28 67.63±8.05 59.30±9.79 0.001 
Immediately 
After Intubation 93.60±12.49 74.73±8.29 83.13±16.74 0.001 
1 minute  After 
Intubation 85.77±12.16 67.53±9.97 76.17±15.94 0.001 
3 minutes  
After Intubation 79.80±12.27 62.63±10.19 71.07±14.29 0.001 
5 minutes  
After Intubation 72.63±10.20 60.00±9.93 67.10±12.20 0.001 
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MEAN ARTERIAL PRESSURE CHANGES (mmHg) 
 
 
 
Group P E M p Value 
Baseline 95.93±7.46 94.07±6.60 96.00±8.81 0.544 
After Premed 93.20±7.49 90.63±6.76 91.30±8.73 0.412 
After Test Drug 90.77±8.56 74.30±7.78 83.30±9.84 0.001 
After Induction 84.00±10.36 81.00±7.34 72.23±9.34 0.001 
Immediately  
After Intubation 108.10±14.19 87.70±8.01 96.87±16.72 0.001 
1 minute  After 
Intubation 100.10±13.49 80.67±9.19 89.97±15.64 0.001 
3 minutes  After 
Intubation 92.77±13.17 75.70±9.01 84.00±13.79 0.001 
5 minutes  After 
Intubation 85.30±11.17 73.30±8.69 79.50±10.73 0.001 
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MMS GRADE(MODIFIED MALLAMPATTI SCORE) 
Grade Group P Group E Group M Total 
Chi Square 
Test 
l 22 24 24 70 
p = 0.695 
ll 7 6 6 19 
lll 1 0 0 1 
Total 30 30 30 90 
 
 
CORMACK LEHANE GRADE 
Grade Group P Group E Group M Total 
Chi Square 
Test 
l 27 22 19 68 
p = 0.166 
ll a 3 6 8 17 
ll b 0 2 3 5 
Total 30 30 30 90 
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LARYNGOSCOPY DURATION 
 
Group N Mean SD ANOVA 
P 30 13.23 2.34 F = 1.070 
E 30 12.87 2.45 p = 0.348 
M 30 13.83 2.93   
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SIDE EFFECTS 
 
HYPOTENSION 
Grade Group P Group E Group M Total Chi Square Test 
Yes 0 1 4 5 
p = 0.133 No 30 29 26 85 
Total 30 30 30 90 
 
BRADYCARDIA 
Grade Group P Group E Group M Total 
Chi Square 
Test 
Yes 0 1 1 2 
p = 0.600 No 30 29 29 88 
Total 30 30 30 90 
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ARRHYTHMIA 
Grade Group P Group E Group M Total 
Yes 0 0 0 0 
No 30 30 30 90 
Total 30 30 30 90 
 
 
There was no incidence of laryngospasm, bronchospasm or 
prolongation of neuromuscular blockade. 
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DISCUSSION 
 
Laryngoscopy and intubation can produce haemodynamic stress response 
charecterised by hypertension and tachycardia. It can also produce 
increase in intracranial pressure. No drug can attenuate this response 
completely. Many drugs have been reported to attenuate this response. 
 
A.A.Vandenberg et al 1 in October 2003, studied attenuation of 
haemodynamic response in Magnesium Sulphate pretreated patients 
undergoing cataract surgery. They compared Esmolol and MgSO4.They 
concluded that Esmolol 4mg/kg prevented increase in heart rate and rate 
pressure product. Mg SO4 40 mg/kg did not prevent response to 
laryngoscopy and intubation. 
 
SapnaBathla,Santhoshkumar et al 4 in 2003, compared efficacy of  IV 
Esmolol  Diltiazem and Magnesium Sulphate, in attenuating  
haemodynamic stress response to laryngoscopy and intubation. Their 
study showed that MgSo4 produced tachycardia and failed to attenuate 
rise in heart rate. Esmolol prevented rise in heart rate though rise in blood 
pressure was suppressed but not prevented. 
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In our study, comparison of  Esmolol 1.5mg/kg, MgSo4 50mg/kg and 
placebo was done in attenuating  haemodynamic stress response to 
laryngoscopy and intubation. The data was analysed using Microsoft 
Excel. Haemodynamic variables were represented by mean and standard 
deviation. Statistical significance was assessed by use of ANOVA and 
Pearson chi square test. TUKEYS HSD was applied to evaluate inter 
group comparisons . 
 
P vaue less than 0.05 was considered as statistically significant. 
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HEART RATE CHANGES: 
 
The baseline heart rate of all groups did not have any statistical 
significance since p value was 0.112. 
 
After the test drug there was significant decrease in heart rate in Esmolol 
group compared to the placebo, whereas there was increase in heart rate 
in Magnesium sulphate group. This result was also observed by M F M 
James et al 5 in 1989 which showed that Magnesium sulphate 
pretreatment increased heart rate  by 13±3.9 beats per minute. In our 
study heart rate increased by 11.8±3.98 beats per minute. 
 
After induction heart rate in all three groups reduced significantly 
compared to baseline. 
 
Immediately after intubation, heart rate increased in all three groups. 
p=0.001(statistically significant).But Esmolol group produced just a little 
increase in heart rate (4±4.4 beats/min). Esmolol produced least increase 
in heart rate compared to baseline. 
  65
 
Both MgSO4 and placebo group produced increase in heart rate response 
but by Tukey HSD it was not significant since both groups had increased 
heart rate by approximately 15-20 beats from baseline. 
 
One minute after intubation heart rate increased significantly between the 
groups. p=0.026.Esmolol produced least increase in heart rate. Both 
group P and M produced increase in heart rate but by Tukey HSD it was 
not significant. 
 
Three minutes after intubation, heart rate between the groups was not 
statistically significant. p=0.167. In Group E heart rate decreased to less 
than baseline. Heart rate changes between group P and E was not 
significant, but between P and M and group E and M it was significant. 
Heart rate continued to be high in group M. 
 
At five minutes after intubation, there was no statistical difference 
p=0.296. The mean heart rate in Group E was less than baseline but 
marginally elevated in group P and M.  
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Juhi Sharma et al 2 when comparing Esmolol and Magnesium Sulphate 
in attenuating pressor response in controlled hypertensive patients stated  
that Magnesium Sulphate produces increase in heart rate. 
 
G.D. Puri et al 16showed increase in heart rate after MgSO4 injection 
and further lncrease with intubation in MgSO4 pretreated coronary artery 
disease patients. 
 
B.Ugur et al 10 in 2007,  showed that Esmolol 1.5mg/kg prevented 
tachycardia and increase in rate pressure  product caused by laryngoscopy 
and intubation in patients with tachycardia. 
 
This result was in accordance with A.Gupta et al 3 in 2009 who showed 
greater attenuation of  heart rate and blood pressure response with 
Esmolol 1.5mg/kg  than Lignocaine.   
 
In this study, Esmolol produced least increase in heart rate. Even three 
minutes after intubation the heart rate continued to be high in group M. 
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The heart rates started coming towards baseline value five minutes after 
intubation. 
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SYSTOLIC BLOOD PRESSURE CHANGES 
 
The baseline systolic blood pressure between the three groups was not 
statistically significant p=0.504. 
 
After test drug there was significant fall in blood pressure between the 
three groups p=0.001.Group E produced the maximum fall in SBP 
followed by group M and P. There was no significance between group P 
and M. But there was significance between group P and E and group E 
and M. 
 
After induction there was significant fall in BP between the three groups 
p=0.001. 
 
Immediately after intubation there was significant in SBP changes 
between the groups. p=0.001.Group E produced  fall in SBP compared to 
baseline. In group M the systolic blood pressure was comparable to the 
baseline and in group P it was higher than the baseline. 
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One minute after intubation, systolic blood pressure was decreased in 
group E and M. Group E produced more fall in BP than group M. There 
was statistical significance between the three groups p=0.001. 
 
Three minutes after intubation there was significant change in SBP 
between the groups. p=0.001.There was no significance between Group E 
and M but there was significance between group P and E and group P and 
M. In group E there was significant fall in BP compared to  the other 
groups. 
 
Five minutes after intubation, there was significance in SBP changes 
between the groups p=0.001. There was statistical significance between 
group P and E but no significance between group P and M and group E 
and M. 
 
These results are in accordance with A.Rathore et al 27 who stated that 
Esmolol 150mg caused significant blunting of rise in systolic blood 
pressure. But in this study we used Esmolol 1.5mg/kg which was enough 
to blunt intubation response. 
 
  70
 Sharma et al 23showed that Esmolol 100mg was safe to blunt 
hemodynamic stress response. 
 
R.W.Allen et al 6 in 1990,  showed no mean increase in systolic blood 
pressure to tracheal intubation in hypertensive proteinuric pregnant 
patients given Magnesium Sulphate. 
 
Overall Group M showed less hypertensive response compared to group 
P, but group E had the least hypertensive response. 
 
 
 
 
  71
DIASTOLIC BLOOD PRESSURE CHANGES 
 
The baseline diastolic blood pressure between the three groups was not 
statistically significant p=0.707. 
 
After test  drug, there was significant fall in BP between the three 
groups.p=0.001 
 
After induction, Magnesium Sulphate produced more fall in diastolic 
blood pressure than Esmolol. There was statistical significance between 
group P and M and between group E and M. 
 
Immediately after intubation, one minute, three minutes and five minutes 
after intubation there were  significant changes in diastolic blood pressure 
between the groups p=0.001.Diastolic blood pressure was increased more 
in group P and to a less extent in group M, but Group E showed fall in BP 
compared to the baseline. 
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K.Montazeri et al 13,showed that pretreatment with different doses of 
Magnesium Sulphate suppressed blood pressure response to laryngoscopy 
and intubation. 
 
A.Ahmed et al 17.,showed that MgSo4 50mg/kg attenuated stress 
response to laryngoscopy and intubation. 
 
Juhi Sharma et al 2 stated that there was no significant difference in 
systolic and diastolic blood pressure between MgSo4 and Esmolol group. 
 
Thus this study showed that Esmolol and Magnesium Sulphate produced 
significant fall in diastolic blood pressure after induction and intubation 
compared to placebo group. 
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MEAN ARTERIAL PRESSURE CHANGES 
 
The baseline mean arterial blood pressure between the three groups was 
not statistically significant p=0.544 
 
After test drug, there was statistical significance of fall in mean arterial 
pressure between the three groups. p=0.001 
 
After induction, group M produced more fall in BP than group E and P. 
 
Immediately after intubation, one minute and three minutes after 
intubation  there were  significant changes in mean arterial  blood 
pressure between the groups p=0.001.Fall in mean arterial  blood pressure 
was  more in group E followed by group M. In group P there was an 
increase in MAP. 
 
K.Pasternak et al 9.,showed that Magnesium Sulphate attenuated 
adrenergic response to tracheal intubation in CABG patients. 
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Sharma et al 23showed that Esmolol 200mg blunts hemodynamic stress 
response  to tracheal intubation in treated hypertensive patients and the 
hemodynamic variables were lower than the basal values. Since our study 
was conducted on non hypertensive patients Esmolol 1.5mg/kg was 
sufficient to blunt stress response and produced hemodynamic variables 
lower than baseline values. 
 
Tetsuro Kagawa et al 28.,showed that IV MgSo4 significantly 
suppressed mean arterial pressure and rate pressure product at the time of 
tracheal intubation. They also stated that no sedative effect was observed. 
Even in our study we observed no sedative effect in group M patients.  
 
Five minutes after intubation, there was statistical significance in mean 
arterial pressure changes between the groups .p=0.001. By Tukey’s HSD 
there was significance between group P and E but no significance 
between group E and M or group P and  M. Group E  had MAP less than 
the baseline. 
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Esmolol and Magnesium Sulphate produced significant fall in mean 
arterial pressure compared to placebo group. 
 
SIDE EFFECTS 
     One patient in group E and four patients in group M had hypotension 
(MAP<60mmHg) .One patient in group M and one patient in group E had 
bradycardia (HR<60/min).There were no incidences of bronchospasm or 
laryngospasm and arrhythmia in any group. There were no cases of 
prolonged neuromuscular blockade or delayed recovery in any group. 
One patient in group M had complaints of  hot flush in the lower 
abdomen when Magnesium Sulphate was being infused which was also 
observed in the study by Fughs et al. 
 
    This study shows that Esmolol attenuates increase in heart rate and 
blood pressure following laryngoscopy and intubation. Magnesium 
Sulphate is also useful in attenuating blood pressure changes but produces 
tachycardia. Hence Esmolol is useful in attenuating stress response 
followed by Magnesium Sulphate compared to a placebo.  
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SUMMARY 
This  randomized  prospective single blinded  study  was  designed  to 
evaluate efficacy of Esmolol and Magnesium sulphate  in attenuating 
hemodynamic stress response to laryngoscopy and intubation .Ninety 
patients of ASA PS I and II were randomly allocated into three groups of 
thirty each. 
P---received normal saline 
E—Esmolol 1.5mg/kg 
M—Magnesium Sulphate 50mg/kg 
The following observations were made 
1) Group E showed maximum attenuation of heart rate and blood 
pressure. 
2) Group M also showed significant attenuation of blood pressure 
response but produced tachycardia on infusion of the drug. Heart rate 
response was not statistically significant compared to group E. 
3) All patients recovered well. 
4) Incidence of side effects was not significant between the groups. 
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CONCLUSION 
 
From this study, it is concluded that hemodynamic changes to 
laryngoscopy and intubation  can be attenuated by giving intravenous 
Esmolol 1.5mg/kg. 
Esmolol is effective in blunting the response followed by Magnesium 
Sulphate which blunts the hypertensive response but produces 
tachycardia during infusion of the drug. 
Placebo was ineffective in blunting hemodynamic stress response to 
laryngoscopy and intubation. 
 
 
 
 
 
 
 
MAGNESIUM  SULPHATE GROUP
S. No NAME AGE SEX WEIGHT IP NO BASELINE AFTER PREMED AFTER TEST DRUG AFTER INDUCTION IMMED AFTER INTUBA1MIN AFTER INTUBAT 3 MIN AFTER INTUBAT5 MIN AFTER INTUBATI MMS CL GRALARYNGOSCOP SIDE EFFECTS
HR SBP DBP MAP HR SBP DBP MAP HR SBP DBPMAP HR SBP DBP MAP HR SBP DBP MAP HR SBP DBP MAP HR SBP DBP MAP HR SBP DBP MAP DURN(SECS) HYPOTEBRADYARRHYTHMIAS
1 VIMALANAND 30 M 58 61516 76 120 76 91 78 120 75 90 82 110 72 85 70 105 70 82 81 108 72 82 79 105 71 82 76 103 70 81 70 101 63 76 I I 9 ` N N N
2 DHANALAXMI 36 F 55 66322 86 136 84 101 92 126 84 98 96 119 77 91 74 108 63 78 106 153 109 124 97 130 95 107 91 116 81 93 87 114 78 90 I I 10 N N N
3 DILLIKUMAR 34 M 50 63449 62 108 71 80 68 109 68 78 73 113 68 77 67 100 56 66 83 114 75 85 91 121 87 98 85 117 77 86 80 106 87 76 I I 13 N N N
4 PRAKASAM 19 M 55 63455 80 136 86 103 97 124 85 98 106 120 77 88 76 93 46 62 105 130 79 96 100 134 80 98 93 106 63 77 88 101 53 69 II I 12 N N N
5 UMA 35 F 47 64679 105 136 86 103 126 122 75 85 125 125 73 84 102 108 57 68 113 123 82 93 103 114 68 78 102 110 67 75 100 111 64 74 I I 15 N N N
6 DIVYABARATHI 16 F 48 65996 104 130 82 98 118 117 71 86 137 113 70 84 95 98 60 73 113 119 80 93 107 90 58 69 104 80 48 59 96 87 53 64 I IIA 13 Y N N
7 BHUVANESWARI 37 F 57 65832 118 132 88 103 121 126 81 96 113 117 76 90 83 108 71 83 113 130 94 106 94 115 74 88 92 115 74 88 91 100 59 73 I I 10 N N N
8 ANJALIDEVI 36 F 67 67736 90 142 90 107 91 115 82 93 90 123 81 95 81 105 66 79 104 150 107 121 102 154 108 123 98 150 104 119 95 124 77 93 I IIB 18 N N N
9 VELU 33 M 74 68003 84 128 86 100 74 121 85 97 86 117 80 92 75 104 71 82 81 124 86 99 82 123 83 96 82 119 82 94 80 116 78 91 I IIA 19 N N N
10 DHANASEKAR 18 M 57 65013 54 118 68 85 56 114 64 81 62 104 62 76 73 93 54 67 76 99 66 77 75 99 65 76 78 98 64 75 80 96 61 73 I I 12 N N N
11 MURALI 44 M 45 68184 76 118 80 93 74 114 78 90 82 101 71 81 82 101 72 82 108 150 117 128 105 140 102 115 103 107 83 91 90 103 80 88 I IIA 15 N N N
12 SANDHYA 17 F 55 68115 96 130 88 102 90 144 100 115 98 141 93 109 88 130 85 100 108 139 99 112 92 129 90 103 88 128 85 99 80 124 84 97 II IIB 18 N N N
13 KARTHICK 45 M 50 69857 67 110 78 89 65 106 66 79 83 100 54 69 72 96 44 61 96 113 58 76 87 109 54 72 86 104 49 67 85 101 46 64 II IIA 22 N N N
14 KAUSALYA 19 F 55 69083 78 110 68 82 90 109 65 80 106 106 57 73 93 89 42 58 106 107 63 78 105 103 53 70 102 99 50 66 98 101 47 65 II IIA 12 Y N N
15 MARIMUTHU 35 F 42 70600 60 134 92 106 64 130 90 103 77 107 72 84 66 95 62 73 96 143 116 125 94 140 112 121 88 135 104 114 80 117 93 101 I I 12 N N N
16 RAVI 42 M 50 73569 64 126 90 102 62 120 86 97 58 116 74 88 52 78 52 61 86 118 80 93 84 112 78 89 78 109 74 86 72 98 64 75 I IIA 13 Y Y N
17 PRITAKUMARI  36 F 35 74890 78 105 71 82 80 98 68 78 90 92 61 71 82 89 57 68 108 117 86 96 106 113 83 93 104 112 83 93 102 98 70 79 I I 12 N N N
18 KOMALA 38 F 55 76925 84 146 92 110 90 128 86 100 115 120 72 88 86 99 57 71 105 149 95 113 99 120 76 104 91 106 68 81 84 106 67 80 I I 13 N N N
19 TAMILSELVI 29 F 50 76902 72 130 80 97 80 127 80 96 86 123 78 93 76 115 75 88 104 150 103 119 103 142 99 113 102 133 93 106 100 130 91 104 I I 12 N N N
20 CHINNAKANU 40 F 70 76639 80 122 74 90 78 120 68 85 74 109 67 81 70 106 63 77 98 160 103 122 89 139 89 106 84 127 82 97 83 121 72 88 I IIB 15 N N N
21 KANIYAMMAL 35 F 45 77742 64 118 80 93 68 103 68 80 64 96 65 75 59 93 63 73 73 105 73 84 69 98 69 79 68 90 64 73 63 89 63 72 I IIA 16 N N N
22 SARRADHA 23 F 62 78179 84 138 80 95 82 127 76 93 82 106 58 74 71 94 52 66 70 97 53 68 72 106 66 79 74 106 67 80 75 113 70 84 I I 10 N N N
23 GEETHA 23 F 43 78192 76 114 80 91 90 113 76 88 103 93 59 70 74 90 54 66 101 98 68 78 95 97 68 78 91 80 60 67 84 84 60 68 I I 14 Y N N
24 VELAN 32 M 50 77753 70 140 98 112 80 131 89 103 95 125 86 99 75 97 56 70 82 109 73 85 84 107 72 84 86 105 68 80 78 101 69 80 II I 11 N N N
25 BASHEERA 20 F 49 78103 84 122 86 98 80 119 73 88 90 105 53 70 81 98 47 64 94 114 72 86 100 112 53 73 98 110 53 72 88 104 50 68 I I 14 N N N
26 MADHINA 24 F 40 81435 100 134 84 101 96 130 83 99 110 129 80 96 102 98 59 72 108 122 86 98 105 121 75 90 103 108 66 80 100 105 65 78 i i 14 N N N
27 SUMATHY 31 F 45 79053 86 110 66 81 84 124 79 94 101 100 63 75 73 87 48 61 101 118 71 87 92 105 62 76 84 104 63 77 85 101 63 76 I IIA 15 N N N
28 KAUSALYA 19 F 47 70605 82 120 72 88 78 118 72 87 96 98 60 73 79 90 54 66 98 130 76 94 90 112 63 79 84 109 62 86 82 108 61 87 I I 14 N N N
29 MOORTHY 43 M 61 76471 90 128 76 93 92 124 72 89 114 118 64 82 82 98 60 73 98 130 74 93 94 109 68 82 92 105 65 78 90 104 63 77 I I 15 N N N
30 SEKAR 45 M 63 72732 94 136 88 104 92 130 74 93 104 122 68 86 91 104 63 77 107 128 78 95 94 105 64 78 95 103 63 80 94 100 62 75 II I 17 N N N
ESMOLOL GROUP
NAME AGE SEX WEIGHT IP NO BASELINE
HR SBP DBP MAP
VIMALKUMAR 21 M 62 61125 78 130 80 97
LAKSHMIKANT 23 M 53 65306 86 120 82 95
AMMU 27 F 60 62668 104 112 80 91
PARIMALA 31 F 68 62557 68 120 78 92
RAMANI 21 M 55 63994 98 130 84 99
INBASEKARAN 31 M 65 58498 84 124 70 89
MYTHILI 20 F 46 62219 82 122 74 90
RAJESWARI 25 F 48 60820 86 126 80 96
GEETHA 22 F 46 62875 104 118 76 87
MUSINAPARVIN                28 F 62 62223 76 102 70 80
PARVIN BANU                    22 F 43 63495 90 120 80 93
CHINAPONNU                35 F 50 64993 74 130 90 103
BALACHANDRAN             28 M 58 65027 76 126 84 98
TAMILMOZHI 18 F 37 65691 124 100 70 80
SELVI 38 F 62 66320 90 120 76 91
KALAIVANI 22 F 38 64673 86 116 88 97
NAVINKUMAR   15 M 35 63457 107 130 84 99
UMA 18 F 37 60214 108 122 78 93
MOHANAPRIYA 16 F 37 65785 105 124 84 97
GUNASEKAR 19 M 54 69503 92 134 80 98
NABISHA 27 F 52 70607 102 128 86 100
ELAVARASAN     26 M 66 71868 86 144 100 115
JAYAKUMAR 60 M 70 73577 76 132 80 97
RAJATHI 30 F 45 73479 78 124 78 93
AJITKUMAR 16 M 44 74918 80 128 74 92
RAMESHKUMA 28 M 65 76471 78 116 72 87
NAGAMMAL 38 F 62 73917 86 126 80 95
RAJKUMAR 40 M 64 74570 88 124 82 96
KAVIARASAN 19 M 45 72153 88 126 74 91
SUSEELA 32 F 59 72063 88 120 86 91
AFTER PREMED AFTER TEST DRUG  AFTER INDU
HR SBP DBP MAP HR SBP DBP MAP HR
70 117 67 77 69 101 54 66 70
82 118 82 94 71 96 65 75 73
90 113 78 90 93 90 69 76 104
73 124 71 89 58 85 48 60 71
94 124 83 97 71 91 54 66 71
72 126 75 92 64 99 53 68 66
81 113 74 84 67 103 57 71 77
98 124 85 98 83 108 77 87 102
106 111 63 74 92 105 61 73 103
80 96 68 77 67 85 51 62 75
83 112 75 87 73 96 62 73 67
72 128 83 98 74 108 78 88 73
71 125 81 96 69 100 59 73 62
118 119 79 92 109 117 82 94 110
86 118 74 89 67 103 57 72 77
90 119 86 97 84 107 70 82 90
124 131 81 98 107 88 58 68 118
96 120 78 92 89 103 69 80 92
104 120 77 91 91 111 69 83 98
100 142 72 95 75 110 53 72 84
100 121 77 92 99 98 63 75 98
67 143 81 102 67 125 60 82 64
75 126 77 93 58 90 60 70 62
90 126 83 97 71 93 62 72 74
78 124 70 88 84 112 64 80 88
74 110 66 81 80 104 62 76 81
74 120 78 92 71 93 57 69 76
80 120 78 92 72 98 68 78 76
84 114 72 86 74 94 63 73 79
87 116 76 89 82 90 52 65 85
UCTION IMM AFTER INTUBATION 1`MIN AFTER INTUBAT
SBP DBP MAP HR SBP DBP MAP HR SBP
120 65 83 83 116 66 76 80 106
93 67 76 88 108 77 87 84 108
94 71 79 105 98 71 80 104 96
98 57 71 65 112 61 78 63 89
111 71 84 78 105 69 81 84 105
114 71 85 68 103 63 76 63 106
110 57 75 80 107 66 81 78 104
100 75 83 103 120 87 98 96 100
102 61 72 108 112 77 87 106 104
92 57 69 87 110 78 89 86 104
115 80 92 84 114 72 86 84 97
120 78 92 80 109 77 88 76 98
113 66 82 76 114 72 86 76 110
117 80 92 114 103 67 79 112 100
110 57 75 80 107 66 80 78 104
113 75 88 96 115 74 87 88 108
122 78 93 114 112 68 83 110 106
102 66 78 104 118 84 95 100 114
119 74 89 92 111 69 83 92 105
123 58 80 97 134 73 93 96 133
111 76 89 110 125 85 98 108 112
99 54 69 99 136 98 111 83 133
94 62 73 70 111 74 86 65 109
106 73 84 76 114 79 91 73 111
113 69 84 92 122 75 91 88 115
109 66 80 94 111 66 81 92 108
107 70 82 91 116 79 91 90 104
99 69 79 78 127 84 98 74 119
107 73 84 106 118 81 93 98 107
98 53 68 102 125 84 98 91 113
TION 3 MIN AFTER INTUBATION 5 MIN AFTER INTUBATION
DBP MAP HR SBP DBP MAP HR SBP DBP
53 67 78 94 50 65 76 95 50
77 87 80 105 71 82 73 102 68
70 79 103 93 69 77 102 80 56
41 57 60 90 42 58 57 93 43
69 81 77 92 62 72 72 92 60
55 72 64 98 53 64 62 99 52
53 66 75 101 50 66 74 104 43
74 83 91 95 70 78 74 96 72
77 85 102 95 48 61 102 90 42
73 83 85 97 71 80 83 87 59
57 69 82 92 54 67 80 94 49
60 73 75 86 56 66 74 85 56
66 81 75 105 61 75 74 101 57
65 77 110 94 59 71 110 89 56
53 70 75 101 50 67 74 104 53
64 79 87 103 51 68 86 98 53
64 78 104 98 63 75 102 97 62
81 92 102 112 79 90 98 108 75
69 81 92 106 58 74 90 107 58
71 92 94 130 56 81 92 125 52
78 89 98 111 78 89 92 110 73
83 100 76 118 73 88 67 107 64
73 85 64 107 73 84 64 106 72
75 87 72 109 72 84 71 105 71
65 82 84 111 60 77 78 107 59
64 79 88 108 66 80 90 107 65
74 84 84 100 70 80 82 98 68
81 94 72 118 80 93 69 116 78
66 80 90 103 65 78 88 105 72
75 88 90 106 69 81 92 99 62
MMS CL GRADE LARYNOSCOPY  SIDE EFFECTS
MAP DURN (secs) HYPOTENSION BRADY ARRHYTH
65 I I 16 N N N
79 I I 11 N N N
64 I II A 12 N N N
60 I IIA 13 Y Y N
71 I I 11 N N N
63 I I 10 N N N
72 I I 10 N N N
80 I I 11 N N N
52 I I 9 Y N N
68 I I 13 N N N
64 I I 10 N N N
66 I I 13 Y N N
72 I IIA 12 N N N
67 I I 12 N N N
70 I IIA 12 N N N
68 I I 14 N N N
74 I I 11 N N N
86 I I 11 N N N
74 I I 11 N N N
76 I I 13 N N N
85 II IIB 16 N N N
78 II IIA 18 N N N
83 II IIB 16 N N N
82 II I 14 N N N
75 I I 12 N N N
79 I I 14 N N N
78 II I 16 N N N
91 II IIA 19 N N N
83 I I 12 N N N
74 I I 14 N N N
CONTROL GROUP 
SL NO NAME AGE SEX WEIGHT IP NO BASELINE
HR SBP DBP
1 MUTHUVEDI 43 F 50 73764 76 120 80
2 BHAVANI 17 F 38 60818 120 122 80
3 ADHIYAMAN 19 M 55 63937 66 136 85
4 KALISHA 40 M 55 65305 52 136 80
5 VENKATESAN 40 M 63 63612 70 122 86
6 SELVI 40 F 57 63174 76 120 82
7 MAGDALINEMARY 32 F 55 63416 88 126 86
8 MUDALIDHARAN 37 M 65 65830 118 140 86
9 MUTHUBHARATHI 28 M 55 67151 88 128 92
10 THIRUMAL 20 M 55 70714 64 142 84
11 BALAJI 17 M 40 70759 66 96 60
12 GEETHA 32 F 57 73083 78 134 82
13 GUNASUNDARI 19 F 51 73595 82 120 72
14 VASANTHI 25 F 64 72061 76 132 80
15 VINODKUMAR 17 M 58 73111 72 120 74
16 SARANYA 18 F 50 79048 64 110 75
17 DEVI 16 F 47 78570 86 126 84
18 SHAHINA 30 F 65 78566 84 126 84
19 SUSEELA 32 F 65 75486 86 144 86
20 SHANTHI 45 F 71 73123 78 143 87
21 VENDA 35 F 50 73081 78 130 84
22 BASHEERA 25 F 45 69849 78 120 80
23 LATHA 33 F 63 78217 78 130 90
24 NAVEENRAJ 18 M 65 80691 88 110 70
25 VIMALA 35 F 58 79023 58 111 77
26 VENNILA 40 F 45 78175 74 126 86
27 LAKSHMI 32 F 62 80144 84 126 84
28 SELVAM 52 M 64 81123 90 130 86
29 MANI 19 M 62 78342 92 128 86
30 BHUVANESWARI 35 F 58 68756 84 118 72
AFTER PREMED                                                      AFTER TEST DRUG AFTER INDU
MAP HR SBP DBP MAP HR SBP DBP MAP HR
93 86 117 79 92 78 94 69 77 80
94 114 120 78 92 99 100 67 78 104
97 70 135 81 92 63 117 73 85 64
99 52 134 80 98 56 113 83 93 55
98 68 114 82 93 58 96 73 81 57
96 82 115 70 85 71 114 69 84 68
99 84 130 88 102 78 114 84 94 75
104 115 135 85 102 109 145 96 112 107
104 74 127 88 101 75 125 87 100 74
103 64 136 84 101 67 124 73 90 62
72 75 95 59 70 74 103 69 80 74
99 93 129 83 98 92 125 82 96 73
88 80 120 77 91 74 114 77 89 68
97 74 130 78 95 74 136 77 97 73
89 75 125 66 86 76 126 71 89 66
87 62 105 65 78 60 106 68 81 54
98 85 121 80 95 84 120 81 95 72
98 80 127 74 92 78 124 73 90 64
105 78 145 80 102 74 146 73 97 75
106 76 142 82 102 75 141 83 102 70
99 85 125 82 96 79 123 80 94 52
94 78 119 79 92 83 116 77 90 68
103 93 122 84 97 89 130 92 105 73
83 80 110 70 83 76 110 74 86 59
88 66 112 73 86 72 93 66 75 74
99 72 122 84 97 74 118 80 93 77
98 80 124 80 95 78 125 80 95 74
101 86 124 82 96 85 125 78 94 102
100 88 124 85 98 90 122 83 96 82
87 80 120 74 89 78 116 70 85 72
UCTION IMMED AFTER INTUBATION 1 MIN AFTER INTUBATION
SBP DBP MAP HR SBP DBP MAP HR SBP DBP
94 70 78 93 117 84 95 88 98 71
103 69 80 121 121 78 92 120 111 73
122 74 85 95 128 86 99 92 127 83
114 83 93 85 163 112 129 80 166 112
97 74 82 105 147 102 117 83 116 86
111 67 82 75 126 81 96 67 101 65
112 83 93 120 148 111 123 115 140 102
144 96 112 138 158 103 121 128 136 92
96 72 80 106 132 95 107 100 130 92
102 67 79 92 151 99 116 73 141 90
107 65 79 106 115 79 91 100 107 68
97 61 73 105 140 98 112 109 140 97
109 58 75 87 124 81 95 86 122 81
105 64 78 107 146 96 113 94 140 92
93 60 71 99 121 76 81 95 107 61
93 52 66 108 124 89 101 98 103 73
106 74 85 116 150 108 122 98 150 98
116 70 85 104 150 108 122 98 141 100
128 59 82 99 153 92 112 92 135 77
136 90 105 99 182 106 131 92 155 98
117 66 83 117 163 110 128 100 153 98
108 72 84 98 127 82 96 84 119 80
110 77 88 105 160 119 133 97 133 95
110 65 80 104 117 72 87 107 117 72
94 66 75 112 116 92 100 110 125 90
93 68 76 97 124 81 95 101 121 81
122 76 91 104 138 96 110 97 145 92
136 94 108 92 128 82 97 88 120 81
118 78 91 116 144 98 113 94 131 87
106 68 81 104 144 92 109 90 132 86
3 MIN AFTER INTUBATION 5 MIN AFTER INTUBATION MMS
MAP HR  SBP DBP MAP HR SBP DBP MAP
80 93 98 72 81 96 101 72 82 I
86 117 107 71 83 116 104 69 81 I
97 84 117 68 81 67 100 60 71 I
130 78 157 109 125 73 136 88 104 II
96 73 99 75 83 64 91 69 76 III
77 67 101 64 76 65 99 63 75 I
115 109 109 76 87 103 106 74 85 I
107 118 131 88 102 116 129 84 99 I
105 98 127 91 103 83 114 79 91 I
107 67 119 76 90 63 106 67 80 I
81 98 107 68 81 95 105 66 79 I
111 78 109 77 88 73 108 74 85 I
95 84 115 73 87 83 106 65 78 I
108 85 105 74 84 82 104 72 82 I
76 85 104 59 74 78 103 59 74 I
83 82 93 64 74 70 80 56 64 I
115 90 141 98 112 82 130 87 101 I
114 82 128 86 100 78 103 71 82 II
96 76 133 73 93 75 132 77 95 II
117 92 147 90 109 84 138 81 100 II
116 95 127 86 100 83 117 72 87 I
93 79 102 71 81 73 96 60 72 I
108 93 150 107 121 84 128 89 100 I
87 88 110 66 81 79 108 63 78 II
102 71 117 87 97 60 92 52 65 I
94 92 121 83 96 80 118 82 94 II
110 95 129 92 104 86 120 86 97 II
94 86 119 80 93 84 118 79 92 I
102 92 128 86 100 91 127 85 99 I
101 88 124 84 97 86 118 78 91 I
CL GRADE  LARYNGO SIDE EFFECTS
DURN(S) HYPO BRADY ARRHYTHM
I 13 N N N
I 9 N N N
I 13 N N N
I 14 N N N
IIA 18 N N N
I 12 N N N
I 11 N N N
I 9 N N N
I 13 N N N
I 13 N N N
I 13 N N N
I 9 N N N
I 11 N N N
I 14 N N N
I 13 N N N
I 10 N N N
I 13 N N N
IIA 17 N N N
I 12 N N N
IIA 16 N N N
I 13 N N N
I 14 N N N
I 14 N N N
I 16 N N N
I 15 N N N
I 13 N N N
I 14 N N N
I 17 N N N
I 12 N N N
I 16 N N N
ESMOLOL GROUP
NAME AGE SEX WEIGHT IP NO BASELINE
HR SBP DBP
VIMALKUMAR 21 M 62 61125 78 130 80
LAKSHMIKANT 23 M 53 65306 86 120 82
AMMU 27 F 60 62668 88 112 80
PARIMALA 31 F 68 62557 68 120 78
RAMANI 21 M 55 63994 98 130 84
INBASEKARAN 31 M 65 58498 84 124 70
MYTHILI 20 F 46 62219 82 122 74
RAJESWARI 25 F 48 60820 86 126 80
GEETHA 22 F 46 62875 104 118 76
MUSINAPARVIN        28 F 62 62223 76 102 70
PARVIN BANU            22 F 43 63495 90 120 80
CHINAPONNU            35 F 50 64993 74 130 90
BALACHANDRAN       28 M 58 65027 76 126 84
TAMILMOZHI 18 F 37 65691 89 100 70
SELVI 38 F 62 66320 90 120 76
KALAIVANI 22 F 38 64673 86 116 88
NAVINKUMAR            15 M 35 63457 88 130 84
UMA 18 F 37 60214 108 122 78
MOHANAPRIYA         16 F 37 65785 90 124 84
GUNASEKAR 19 M 54 69503 92 134 80
NABISHA 27 F 52 70607 102 128 86
ELAVARASAN             26 M 66 71868 86 144 100
JAYAKUMAR 60 M 70 73577 76 132 80
RAJATHI 30 F 45 73479 78 124 78
AJITKUMAR 16 M 44 74918 80 128 74
RAMESHKUMAR        28 M 65 76471 78 116 72
NAGAMMAL 38 F 62 73917 86 126 80
RAJKUMAR 40 M 64 74570 88 124 82
KAVIARASAN 19 M 45 72153 88 126 74
SUSEELA 32 F 59 72063 88 120 86
AFTER PREMED AFTER TEST DRUG 
MAP HR SBP DBP MAP HR SBP DBP MAP
97 70 117 67 77 69 101 54 66
95 82 118 82 94 71 96 65 75
91 90 113 78 90 93 90 69 76
92 73 124 71 89 58 85 48 60
99 94 124 83 97 71 91 54 66
89 72 126 75 92 64 99 53 68
90 81 113 74 84 67 103 57 71
96 98 124 85 98 83 108 77 87
87 106 111 63 74 92 105 61 73
80 80 96 68 77 67 85 51 62
93 83 112 75 87 73 96 62 73
103 72 128 83 98 74 108 78 88
98 71 125 81 96 69 100 59 73
80 118 119 79 92 109 117 82 94
91 86 118 74 89 67 103 57 72
97 90 119 86 97 84 107 70 82
99 124 131 81 98 107 88 58 68
93 96 120 78 92 89 103 69 80
97 104 120 77 91 91 111 69 83
98 100 142 72 95 75 110 53 72
100 100 121 77 92 99 98 63 75
115 67 143 81 102 67 125 60 82
97 75 126 77 93 58 90 60 70
93 90 126 83 97 71 93 62 72
92 78 124 70 88 84 112 64 80
87 74 110 66 81 80 104 62 76
95 74 120 78 92 71 93 57 69
96 80 120 78 92 72 98 68 78
91 84 114 72 86 74 94 63 73
91 87 116 76 89 82 90 52 65
AFTER INDUCTION IMM AFTER INTUBATION  1`MIN AFT
HR SBP DBP MAP HR SBP DBP MAP HR
70 120 65 83 83 116 66 76 80
73 93 67 76 88 108 77 87 84
104 94 71 79 105 98 71 80 104
71 98 57 71 65 112 61 78 63
71 111 71 84 78 105 69 81 84
66 114 71 85 68 103 63 76 63
77 110 57 75 80 107 66 81 78
102 100 75 83 103 120 87 98 96
103 102 61 72 108 112 77 87 106
75 92 57 69 87 110 78 89 86
67 115 80 92 84 114 72 86 84
73 120 78 92 80 109 77 88 76
62 113 66 82 76 114 72 86 76
110 117 80 92 114 103 67 79 112
77 110 57 75 80 107 66 80 78
90 113 75 88 96 115 74 87 88
118 122 78 93 114 112 68 83 110
92 102 66 78 104 118 84 95 100
98 119 74 89 92 111 69 83 92
84 123 58 80 97 134 73 93 96
98 111 76 89 110 125 85 98 108
64 99 54 69 99 136 98 111 83
62 94 62 73 70 111 74 86 65
74 106 73 84 76 114 79 91 73
88 113 69 84 92 122 75 91 88
81 109 66 80 94 111 66 81 92
76 107 70 82 91 116 79 91 90
76 99 69 79 78 127 84 98 74
79 107 73 84 106 118 81 93 98
85 98 53 68 102 125 84 98 91
ER INTUBATION 3 MIN AFTER INTUBATION 5 MIN AFTER INTUBATI
SBP DBP MAP HR SBP DBP MAP HR SBP
106 53 67 78 94 50 65 76 95
108 77 87 80 105 71 82 73 102
96 70 79 103 93 69 77 102 80
89 41 57 60 90 42 58 57 93
105 69 81 77 92 62 72 72 92
106 55 72 64 98 53 64 62 99
104 53 66 75 101 50 66 74 104
100 74 83 91 95 70 78 74 96
104 77 85 102 95 48 61 102 90
104 73 83 85 97 71 80 83 87
97 57 69 82 92 54 67 80 94
98 60 73 75 86 56 66 74 85
110 66 81 75 105 61 75 74 101
100 65 77 110 94 59 71 110 89
104 53 70 75 101 50 67 74 104
108 64 79 87 103 51 68 86 98
106 64 78 104 98 63 75 102 97
114 81 92 102 112 79 90 98 108
105 69 81 92 106 58 74 90 107
133 71 92 94 130 56 81 92 125
112 78 89 98 111 78 89 92 110
133 83 100 76 118 73 88 67 107
109 73 85 64 107 73 84 64 106
111 75 87 72 109 72 84 71 105
115 65 82 84 111 60 77 78 107
108 64 79 88 108 66 80 90 107
104 74 84 84 100 70 80 82 98
119 81 94 72 118 80 93 69 116
107 66 80 90 103 65 78 88 105
113 75 88 90 106 69 81 92 99
ION MMS CL GRADE LARYNOSCOPY  SIDE EFFECTS
DBP MAP DURN (secs) HYPOTENSION BRADY ARRHYTH
50 65 I I 16 N N N
68 79 I I 11 N N N
56 64 I II A 12 N N N
43 60 I IIA 13 Y y N
60 71 I I 11 N N N
52 63 I I 10 N N N
43 72 I I 10 N N N
72 80 I I 11 N N N
42 52 I I 9 N N N
59 68 I I 13 N N N
49 64 I I 10 N N N
56 66 I I 13 N N N
57 72 I IIA 12 N N N
56 67 I I 12 N N N
53 70 I IIA 12 N N N
53 68 I I 14 N N N
62 74 I I 11 N N N
75 86 I I 11 N N N
58 74 I I 11 N N N
52 76 I I 13 N N N
73 85 II IIB 16 N N N
64 78 II IIA 18 N N N
72 83 II IIB 16 N N N
71 82 II I 14 N N N
59 75 I I 12 N N N
65 79 I I 14 N N N
68 78 II I 16 N N N
78 91 II IIA 19 N N N
72 83 I I 12 N N N
62 74 I I 14 N N N
